Low ivermectin use among 5- to 6-year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa.


Journal

International health
ISSN: 1876-3405
Titre abrégé: Int Health
Pays: England
ID NLM: 101517095

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 18 03 2019
revised: 02 05 2019
accepted: 06 06 2019
pubmed: 30 6 2019
medline: 28 4 2020
entrez: 29 6 2019
Statut: ppublish

Résumé

During door-to-door surveys in onchocerciasis-endemic regions in Africa, the age-specific ivermectin coverage in 29 722 individuals was assessed. Children 5-6 y of age had significantly lower coverage compared with older participants. Insufficient ivermectin intake among young children could prolong onchocerciasis elimination prospects, as they may serve as human reservoirs of Onchocerca volvulus; moreover, it increases the risk of developing onchocerciasis-associated epilepsy (OAE). The causes of the low ivermectin coverage observed among children 5-6 y of age need to be explored. Integrating ivermectin distribution into chemoprophylaxis strategies for other neglected diseases could increase coverage in a cost-effective manner.

Identifiants

pubmed: 31251354
pii: 5524822
doi: 10.1093/inthealth/ihz044
pmc: PMC6964214
doi:

Substances chimiques

Ivermectin 70288-86-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-75

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Références

PLoS Negl Trop Dis. 2017 Jul 14;11(7):e0005732
pubmed: 28708828
Lancet Infect Dis. 2018 Nov;18(11):1278-1286
pubmed: 30268645
Infect Dis Poverty. 2018 Dec 3;7(1):114
pubmed: 30501640
Seizure. 2018 Dec;63:93-101
pubmed: 30468964
Infect Dis Poverty. 2018 Jun 20;7(1):64
pubmed: 29921319
Int Health. 2019 Sep 2;11(5):370-378
pubmed: 30845318
Infect Dis Poverty. 2019 Jan 23;8(1):8
pubmed: 30670093
PLoS Negl Trop Dis. 2016 May 03;10(5):e0004478
pubmed: 27139245
Int J Infect Dis. 2019 Feb;79:187-194
pubmed: 30711145

Auteurs

J N Siewe Fodjo (JN)

Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Wilrijk, Antwerp, Belgium.

F Mubiru (F)

Infectious Disease Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.

C Ukaga (C)

Imo State University, PMB 2000, Okigwe Rd, Ugwu Orji, Owerri, Nigeria.

M Y Logora (MY)

Neglected Tropical Diseases Unit, Ministry of Health, Ministry of Health Ministerial Complex, P.O. Box 88, Juba, South Sudan.

B P Mmbando (BP)

National Institute for Medical Research, Tanga Center, P.O. Box 5004, Tanga, Tanzania.

M Mandro (M)

Provincial Health Division Ituri, Ministry of Health, P.O. Box 185, Bunia, Democratic Republic of Congo.

A K Njamnshi (AK)

Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon & Brain Research Africa Initiative (BRAIN), P. O. Box 87, Yaounde, Cameroon.

R Colebunders (R)

Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Wilrijk, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH